Marvel Biosciences reports MB-204 preclinical results in Fragile X model

August 5, 2026 5:00 AM

Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) reported preclinical data showing its lead drug candidate, MB-204, restored behavioral and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found